Anti–CD20-hIFNα completely cures established human xenograft tumors. (A-C) Tumor growth in mice (n = 5-7 per group) inoculated subcutaneously with Daudi cells and treated as indicated with 3 weekly doses of 30 μg of fusion protein, the equivalent molar concentration of rituximab, or HBSS. Treatment was administered 30, 37, and 44 days after tumor inoculation (arrows) to mice with tumors at least 0.5 cm in diameter. HBSS was injected as a control. Symbols represent individual mice. (D) Survival curves for the mice whose tumor growth is shown in panels A-C. *P = .02.